Colorectal Cancer (CRC) At A Glance:

Colorectal cancer is the 4th most commonly diagnosed of all patients with earlier-stage CRC will eventually develop metastases. Approximately 21% of colorectal cancer patients have metastatic disease at diagnosis.

The BRAF Mutation in Metastatic Colorectal Cancer

There are a variety of gene mutations that can lead to metastatic colorectal cancer, including KRAS, NRAS and BRAF.

BRAF mutations are detected almost exclusively in patients with RAS wild-type CRC and V600 is the most common BRAF mutation.

Outcomes in patients with BRAF-mutant mCRC in later lines of therapy are approximately:
- 4 - 6 months mOS
- 2-3 months mPFS
- 4-8% ORR

Currently, there are no FDA-approved therapies specifically indicated for patients with BRAF-mutant metastatic colorectal cancer.

The Unmet Need:

Patients with BRAF-mutant metastatic colorectal cancer generally have a poor prognosis with currently available regimens.

Because of the strong prognostic value in determining the presence of a BRAF mutation, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend that all patients with metastatic colorectal cancer should be tested at diagnosis.

Understanding BRAF-Mutant Metastatic Colorectal Cancer (mCRC)

DID YOU KNOW the BRAF mutation is present in up to 15% of all patients with metastatic colorectal cancer?1,2

References:
4. Mutations that can lead to metastatic colorectal cancer. Br J Cancer.
6. KRAS and NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a randomized, phase III, open-label, non-inferiority trial (CHRISTIAN-2). Lancet Oncol. 2010;11(8):753-762.
7. KRAS and NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a randomized, phase III, open-label, non-inferiority trial (CHRISTIAN-2). Lancet Oncol. 2010;11(8):753-762.
15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.4.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.